Literature DB >> 19174414

Management of neonatal abstinence syndrome: a national survey and review of practice.

M J O'Grady1, J Hopewell, M J White.   

Abstract

AIM: To ascertain the present management of neonatal abstinence syndrome (NAS) in neonatal units in the United Kingdom (UK) and Ireland.
METHODS: Postal questionnaire to 235 neonatal units, with telephone follow-up of non-respondents.
RESULTS: The response rate was 90%, and 96% of respondents had a formal NAS guideline. The median number of infants treated annually for NAS was 6 (range 1-100). The method of Finnegan was the most widely used scoring system (52%). Morphine sulphate was the most commonly used first line agent for both opiate (92%) and polysubstance (69%) withdrawal. Dosing regimens varied widely. Units using a maximum daily morphine dose of <400 microg/kg/day were more likely to require the addition of a second agent (76% vs 58%, p = 0.027). Phenobarbitone was the drug of choice to treat seizures secondary to both opiate and polydrug withdrawal in 73% and 81% of units, respectively. 29% of units allowed infants to be discharged home on medication. 58% of these allowed administration of opiates in the community and in almost half of cases this was managed by a parent. Mothers on methadone whose serology was positive for hepatitis B and/or C were four times more likely to be discouraged from breastfeeding.
CONCLUSIONS: The majority of units currently use an opiate as the drug of first choice as recommended. Doses utilised and second agents added vary significantly between units. Many of our findings reflect the lack of high-quality randomised studies regarding management of NAS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174414     DOI: 10.1136/adc.2008.152769

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  32 in total

1.  Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Authors:  Walter K Kraft; Kevin Dysart; Jay S Greenspan; Eric Gibson; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Addiction       Date:  2010-10-06       Impact factor: 6.526

2.  Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome.

Authors:  Adam J Czynski; Jonathan M Davis; Lynne M Dansereau; Barbara Engelhardt; Peter Marro; Debra L Bogen; Mark L Hudak; Jeffrey Shenberger; Elisha M Wachman; Erica L Oliveira; Barry M Lester
Journal:  J Pediatr       Date:  2020-01-24       Impact factor: 4.406

3.  The worldwide opioid epidemic: implications for treatment and research in pregnancy and the newborn.

Authors:  David Knoppert
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

4.  Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study.

Authors:  Lauren E Kelly; David Knoppert; Henry Roukema; Michael J Rieder; Gideon Koren
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

5.  Wide Variation Found in Care of Opioid-Exposed Newborns.

Authors:  Debra L Bogen; Bonny L Whalen; Laura R Kair; Mark Vining; Beth A King
Journal:  Acad Pediatr       Date:  2016-11-23       Impact factor: 3.107

6.  Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011.

Authors:  S W Patrick; H C Kaplan; M Passarella; M M Davis; S A Lorch
Journal:  J Perinatol       Date:  2014-06-12       Impact factor: 2.521

7.  Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting.

Authors:  C H Backes; C R Backes; D Gardner; C A Nankervis; P J Giannone; L Cordero
Journal:  J Perinatol       Date:  2011-08-18       Impact factor: 2.521

Review 8.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

9.  Opiate-induced changes in brain adenosine levels and narcotic drug responses.

Authors:  M Wu; P Sahbaie; M Zheng; R Lobato; D Boison; J D Clark; G Peltz
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

10.  Neonatal abstinence syndrome--postnatal ward versus neonatal unit management.

Authors:  Tolulope Saiki; Silke Lee; Simon Hannam; Anne Greenough
Journal:  Eur J Pediatr       Date:  2009-05-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.